HUS Secretary Robert F. Kennedy Jr. announced that the FDA plans to review peptides for potential inclusion on the 503A bulk list, a designation that allows drugs to be compounded on individual prescribed basis rather than mass producing. This could potentially boost Hims & Hers' high-margin compounded GLP-1 business. The telehealth company has been building towards a peptide business for years and is looking to expand access to peptide therapies. The company's CEO, Andrew Dudum, has called peptide demand "future-facing innovation" and is exploring ways to introduce peptide therapy into regulated, physician-led care. However, while the potential for peptides to boost the company's bottom line is still uncertain, it will take time for peptide use to boost its bottom line.